...He also serves as CSO of CNS play Syndesi Therapeutics S.A....

...and fairly specific event in AD, which is one of the reasons for targeting ACh,” Syndesi...
...synapses, he added, the company’s modulators could improve synaptic transmission regardless of dependence on ACh. Syndesi...
...in Syndesi; details of the licensing agreement for the SV2A modulators are undisclosed. COMPANY PROFILE Syndesi Therapeutics S.A....

...general manager of U.S. Oncology at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). Neurology company Syndesi Therapeutics S.A....

...UCB S.A. (Euronext:UCB) spinout Syndesi Therapeutics S.A. (Louvain-la-Neuve, Belgium) launched with a €17 million ($21.1 million) series A...
...granted the company exclusive, worldwide rights to a platform of synaptic vesicle protein (SV2A) modulators. Syndesi...
...proof of concept to treat cognitive impairment in patients with Alzheimer’s disease. Syndesi Therapeutics S.A., Louvain-la-Neuve, Belgium Alicia Parker Syndesi...